Your doctor may also prescribe Mounjaro off-label for weight management ... (An active ingredient is what makes a drug work.) Another drug, Zepbound, also contains the same active ingredient ...
In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...
Shares of Eli Lilly & Co. were headed for their worst day in nearly four years on Tuesday after the drugmaker provided a fourth-quarter revenue outlook that was below expectations, citing slower ...
Why it matters: Lilly's growth prospects are driven by Mounjaro and Zepbound, and shortfalls in sales could portend weaker long-term potential for this market. Lilly is positioned to remain the ...
Once again, the drugmaker reported sales of its blockbuster GLP-1 medicines Zepbound and Mounjaro that missed Wall Street estimates. It was the second consecutive miss for the two closely watched ...
GLP-1 drugs have become all the rage for weight loss, with sales for drugs like Novo Nordisk's Ozempic and Eli Lilly's (NYSE: ...
Sales of Eli Lilly's (LLY) blockbuster diabetes and weight loss drugs, Mounjaro and Zepbound, are very strong, but they're not quite as robust as the company and analysts had anticipated in Q4.
Weight-loss drugs like Ozempic and Mounjaro are so prevalent that 1 in ... also includes Wegovy and Zepbound. GLP-1s were developed to treat diabetes, but they have become popular weight-loss ...
Lilly expects $3.5 billion in Mounjaro sales in the fourth quarter, and $1.9 billion for Zepbound. Analysts had expected the drugs to bring in $5.35 billion and $2.08 billion, respectively ...
Management attributed this lowered guidance to the slowed sales growth of its tirzepatide products in the fourth quarter — diabetes drug Mounjaro added $3.5 billion, while obesity drug Zepbound ...
Mounjaro vs. Ozempic ... help those with type 2 diabetes manage blood sugar and prescribed off-label for weight loss. Zepbound is another brand name for tirzepatide — and this one is FDA ...